April 1, 2026
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Investors
Clinical Development Pipeline
Learn More
Quarterly Results
View Results
2025 Year in Review
View This Report
Key Ratios
Key Financial Ratios
Sustainability Report
Learn More
Latest Sustainability Developments
View Stories
Investor Email Alerts
Sign up to receive email alerts for various types of investor content.